Loading stock data…
OmniAb (OABI)
$2.03-0.01 (-0.49%)
Market ClosedLast close Jul 24
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
OmniAb, Inc. in the Healthcare sector is trading at $2.03 with a market capitalization of $302M. Wall Street consensus targets $7.33 (6 analysts), implying a +261.2% move over the next 12 months. The stock is currently 27% below its 52-week high of $2.79, remaining 8.0% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +261.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 25) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $14.43M↑ | $8.38M↑ | $2.24M↓ | $3.90M↓ | $4.15M |
| Gross Profit | $14.41M↑ | $8.37M↑ | $2.21M↓ | $3.63M↓ | $4.15M |
| Operating Income | -$7.83M↑ | -$15.77M↑ | -$18.14M↑ | -$19.22M↓ | -$18.84M |
| Net Income | -$7.71M↑ | -$14.18M↑ | -$16.52M↓ | -$15.88M↑ | -$18.20M |
Peer Comparison
JNJUNHPFE
Fundamentals
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The compa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$301.54M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-20.67%
Volume
Today's trading volume
302,673
Recent News
The Cancer Therapy Strategy VERAXA Is Betting the Company On
By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it expects BiTAC molecules to be the company’s main value drivers and to dominate its pipeline development in the upcoming years, hence receiving VERAXA’s main share of investments to have a first BiTAC-T cell engager candidate ready by early 2028. The company stated its half-year progress […] The post The Cancer Therapy Strategy VERAXA Is Betting the Company On appeared first on ExecEdge.
OmniAb (OABI) Gains More Than 38% Over 6 Months, Can It Go Higher?
OmniAb, Inc. (NASDAQ:OABI) is one of the Best Small-Cap Growth Stocks to Invest In Now. The stock has gained more than 38% over the past 6 months and around 74% since the release of its fiscal Q1 2026 earnings and business update. The company reported earnings on May 7, showing significant improvement and prompting an […]
Companies Like OmniAb (NASDAQ:OABI) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
OmniAb (OABI) Q1 2026 Earnings Transcript
OmniAb delivered a very strong start to the year, largely driven by advancement of our partner programs. The progression of these programs gives us a growing line of sight into potential for future milestones and new royalties as our partners' programs advance. In addition, our innovations and our technologies are designed to differentiate OmniAb as a licensing partner and more broadly as a business.
OmniAb, Inc. Q1 2026 Earnings Call Summary
Moby summary of OmniAb, Inc.'s Q1 2026 earnings call